Then, it was time to listen to Åsa Petersén, from Sweden, a respected HD expert who is a Professor of Neuroscience and Consultant Psychiatrist in Lund. Åsa talked about some of the studies being held in Sweden and shared some information about a new study that will look at CAA interruptions and its importance for when you start developing symptoms of Huntington’s disease.

Lasse Pihlstrøm, a well-known HD Neurologist and Researcher at Oslo University Hospital, presented some data about the Enroll-HD study, the largest observational study ever conducted in HD, which is also being done in Norway. Lasse also talked about a study recently started at his centre which will test the impact of high doses of vitamin B3 on people affected by HD in Norway.

Lastly, Simon Mølgaard, the CEO of Teitur Trophics, a biotech company from Denmark, presented their work on a first-in-class disease-modifying peptide that targets several key pathologies in HD. The presentations were followed by a multilingual Q&A session, where all participants had the opportunity to ask questions and share their comments or doubts.